$Antiplatelet therapy to prevent thrombosis after hip fracture. Rationale for a randomised trial.$

Antiplatelet therapy to prevent thrombosis after hip fracture. Rationale for a randomised trial.

Opis bibliograficzny
Główni autorzy:	MacMahon, S, Rodgers, A, Collins, R, Farrell, B
Format:	Journal article
Język:	English
Wydane:	1994

Podobne zapisy

ANTIPLATELET THERAPY TO PREVENT THROMBOSIS AFTER HIP FRACTURE - REPLY
od: Macmahon, S, i wsp.
Wydane: (1995)

The pulmonary embolism prevention (PEP) trial: Effects of low-dose aspirin on major vascular events in patients with hip fracture
od: Prentice, C, i wsp.
Wydane: (1999)

Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement
od: Kyung Won Kim, i wsp.
Wydane: (2021-01-01)

Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration.
od: Collins, R, i wsp.
Wydane: (1994)

A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial
od: de Haan RJ, i wsp.
Wydane: (2010-05-01)

Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials.
od: Yusuf, S, i wsp.
Wydane: (1988)

A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery.
od: Neal, B, i wsp.
Wydane: (2000)

TRIALS OF ANTIPLATELET THERAPY - REPLY
od: Baigent, C, i wsp.
Wydane: (1994)

PEP trial - Reply
od: Collins, R, i wsp.
Wydane: (2000)

HEPARIN IN THE PRESENCE OR ABSENCE OF ANTIPLATELET THERAPY - AN OVERVIEW OF RANDOMIZED TRIALS IN ACUTE MYOCARDIAL-INFARCTION
od: Macmahon, S, i wsp.
Wydane: (1992)

No effect of low-dose aspirin for the prevention of heterotopic bone formation after total hip replacement: a randomized trial of 2,649 patients.
od: Neal, B, i wsp.
Wydane: (2000)

Protease‐activated receptor antagonists prevent thrombosis when dual antiplatelet therapy is insufficient in an occlusive thrombosis microfluidic model
od: Jess Berry, i wsp.
Wydane: (2022-03-01)

Gap in secondary fracture prevention (but not in primary prevention of infection and thrombosis) following a hip fracture: the spare-hip prospective cohort
od: Prieto-Alhambra, D, i wsp.
Wydane: (2017)

Trials of antiplatelet therapy.
od: Bounameaux, H
Wydane: (1994)

Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials.
od: Collins, R, i wsp.
Wydane: (2001)

Inhibiting novel mechanisms of thrombosis: next-generation antiplatelet therapy
od: Mark R. Thomas, i wsp.
Wydane: (2021-01-01)

Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials.
od: Collins, R, i wsp.
Wydane: (1996)

Assessing operative delay and complications in hip fracture patients on anticoagulants and antiplatelets
od: Asheesh R Elete, i wsp.
Wydane: (2023-03-01)

Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study)
od: Kawamori Ryuzo, i wsp.
Wydane: (2006-08-01)

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
od: Collaboration, A
Wydane: (2002)

Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial
od: Reid, I, i wsp.
Wydane: (2001)

Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses.
od: Melissa Li, i wsp.
Wydane: (2014-01-01)

What should be done when appropriate antiplatelet therapy fails to prevent stent thrombosis? Two case reports
od: Sungman Hong, i wsp.
Wydane: (2023-06-01)

The impact of antiplatelet therapy on pelvic fracture outcomes
od: Christy Jonathan, i wsp.
Wydane: (2011-01-01)

Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): rationale and design of a phase II double blind randomised controlled trial
od: Desborough, M, i wsp.
Wydane: (2019)

ANTIPLATELET THERAPY IN THE PREVENTION OF CEREBROVASCULAR ACCIDENTS
od: O. V. Rodionova, i wsp.
Wydane: (2017-03-01)

A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
od: Nikola Sprigg, i wsp.
Wydane: (2008-08-01)

Impact of antiplatelet therapy on microvascular thrombosis during ST-elevation myocardial infarction
od: Sophia Khattak, i wsp.
Wydane: (2024-03-01)

In-Stent Thrombosis after Antiplatelet Therapy Conversion while Awaiting Coronary Bypass
od: Nathan Burke, i wsp.
Wydane: (2020-10-01)

Association Between Simultaneous Bilateral Total Hip Arthroplasty Without Any Anticoagulant or Antiplatelet Therapy and Deep Venous Thrombosis: A Cohort Study
od: Masaki Hatano, MD, i wsp.
Wydane: (2022-02-01)

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
od: Altman, R, i wsp.
Wydane: (1994)

Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial
od: Vijay Kunadian, i wsp.
Wydane: (2019-08-01)

Stroke, coronary heart disease, cholesterol and blood pressure
od: Lewington, S, i wsp.
Wydane: (1997)

The Effect of Pre-operative use of Antiplatelets and Anticoagulants on Time to Surgery in Hip Fracture Patients
od: Shamsuri NS, i wsp.
Wydane: (2023-03-01)

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.
od: Neal, B, i wsp.
Wydane: (2000)

Antiplatelet therapy in secondary prevention of ischemic stroke
od: V. A. Parfyonov, i wsp.
Wydane: (2015-12-01)

Precision antiplatelet therapy for the prevention of ischaemic stroke
od: David Wang

HIP fracture Supplemental Therapy to Enhance Recovery (HIPSTER): a protocol for a randomised controlled trial
od: Belinda J Gabbe, i wsp.
Wydane: (2024-01-01)

Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease.
od: Reid, I, i wsp.
Wydane: (2001)

A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study.
od: Shepstone, L, i wsp.
Wydane: (2012)